Cargando…
Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response
Vitiligo is an acquired depigmentation skin disease caused by immune-mediated death of melanocytes. The most common treatment for vitiligo is narrow band ultraviolet B phototherapy, which often is combined with topical therapies such as tacrolimus. However, patients’ responses to these treatments sh...
Autores principales: | Yang, Qianli, Zhang, Guohong, Su, Mingwan, Leung, Gigi, Lui, Harvey, Zhou, Pingyu, Wu, Yan, Zhou, Joshua, Xu, Jinhua, Zhang, Xuejun, Zhou, Youwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015777/ https://www.ncbi.nlm.nih.gov/pubmed/33815367 http://dx.doi.org/10.3389/fimmu.2021.613031 |
Ejemplares similares
-
Transcriptome Analysis Reveals Markers of Aberrantly Activated Innate Immunity in Vitiligo Lesional and Non-Lesional Skin
por: Yu, Richard, et al.
Publicado: (2012) -
Correction: Transcriptome Analysis Reveals Markers of Aberrantly Activated Innate Immunity in Vitiligo Lesional and Non-Lesional Skin
por: Yu, Richard, et al.
Publicado: (2013) -
Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001)
por: Liu, Lisa, et al.
Publicado: (2023) -
Hyperhidrosis Prevalence and Demographical Characteristics in Dermatology Outpatients in Shanghai and Vancouver
por: Liu, Yudan, et al.
Publicado: (2016) -
Advances in vitiligo: Update on therapeutic targets
por: Feng, Yifei, et al.
Publicado: (2022)